Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 3

4438 - Multi-institutional evaluation of therapeutic management for oligometastatic cancer prostate recurrence with choline-PET/CT


30 Sep 2019


Poster Display session 3


Tumour Site

Prostate Cancer


Morgane Guibert-broudic


Annals of Oncology (2019) 30 (suppl_5): v325-v355. 10.1093/annonc/mdz248


M. Guibert-broudic1, T. Dubergé2, A. AUTRET3, P. CARRIER4, N. Salem5, J. Walz6, I. Brenot-Rossi7, G. Gravis8

Author affiliations

  • 1 Radiotherapy, Institut Paoli-Calmettes, 13009 - Marseille/FR
  • 2 Radiotherapy, Croix-Rouge Française, 83100 - TOULON/FR
  • 3 Biostatistic, Institut Paoli-Calmettes, 13009 - MARSEILLE/FR
  • 4 Nuclear Medicine, Centre hospitalier Toulon - La Seyne, 83100 - TOULON/FR
  • 5 Radiotherapy, Institut Paoli-Calmettes, 13009 - MARSEILLE/FR
  • 6 Chirurgie Oncologique 2, Institute Paoli Calmettes, 13274 - Marseille/FR
  • 7 Nuclear Medicine, Institut Paoli-Calmettes, 13009 - MARSEILLE/FR
  • 8 Medical Oncology, Institute Paoli Calmettes, 13274 - Marseille/FR


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 4438


Choline Positron Emission Tomography – Computed Tomography (Choline PET/CT) allows for the diagnosis of oligometastatic (OM) Prostate Cancer (PCa) recurrence that could be treated with a curative intent. The aim of the study was to evaluate the different therapeutic approaches and outcomes for first OM recurrence.


This multi-institutional, retrospective study included patients with a hormone-sensitive biochemical PCa recurrence after an initial curative local treatment, and with at least 1 to 5 Choline PET/CT-diagnosed metastatic lesions. Primary endpoint was Biochemical Recurrence Free Survival (BRFS). Secondary endpoints were Metastatic Recurrence-Free Survival (MRFS) and Androgen Deprivation Therapy-Free Survival (ADT-FS).


Between October 2012 and December 2016, 177 patients were included. Sixty-eight patients (38.4%) received an ADT alone, 72 (40.7%) received an External Beam Radiation Therapy (EBRT) – ADT association, 28 (15.8%) received an EBRT, 6 (3.4%) received a surgery, and 2 (1.1%) received a surgery with ADT. Median follow-up was 49 months [95%CI, 44.3-53.4]. Among patients who received non-standard treatment, 55% avoided long-term ADT. Grade 3 acute and late toxicities were rare (0.8% and 2.5% respectively). The median BRFS, MRFS and ADT-FS were 42 [95%CI, 37-51], 61 [95%CI, 45-81], and 53 [95%CI, 45-60] months, respectively. In multivariate analysis, concomitant ADT with MDT and "regional" EBRT combined with MDT significantly improved BRFS (p < 0.0001 and p = 0.0113 respectively) and MRFS (p = 0.0005 and p = 0.0013 respectively). In multivariate analysis, a PSA-doubling time of > 3 months had a statistically significant positive impact on MRFS (p = 0.0496) and ADT-FS (p = 0.0007). The overall and disease specific survivals were 87% and 97% respectively at 5 years. The median incidence of castration resistant PCa was 80 months.


In patients with hormone-sensitive OM PCa recurrence after initial local treatment, BRFS and MRFS were significantly improved when concomitant ADT and "regional" EBRT were combined with MDT.

Clinical trial identification

OMPPC-IPC 2018-059.

Editorial acknowledgement

Legal entity responsible for the study

Institute Paoli-Calmettes.


Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.